UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk

PloS one, 2023-09, Vol.18 (9), p.e0291330-e0291330

2023

Link zum Volltext

Verfügbarkeit prüfen

Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation

Arthritis research & therapy, 2024-04, Vol.26 (1), p.86-86, Article 86

2024

Link zum Volltext

Verfügbarkeit prüfen

Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial

Arthritis research & therapy, 2022-12, Vol.24 (1), p.281-8, Article 281

2022

Link zum Volltext

Verfügbarkeit prüfen

Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study

Rheumatology and therapy., 2020-09, Vol.7 (3), p.639-648

2020

Link zum Volltext

Verfügbarkeit prüfen

Systemic Urate Deposition: An Unrecognized Complication of Gout?

Journal of clinical medicine, 2020-10, Vol.9 (10), p.3204

2020

Link zum Volltext

Verfügbarkeit prüfen

A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study

Arthritis research & therapy, 2022-08, Vol.24 (1), p.1-208, Article 208

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparison Between Early-Onset and Common Gout: A Systematic Literature Review

Rheumatology and therapy., 2023-08, Vol.10 (4), p.809-823

2023

Link zum Volltext

Verfügbarkeit prüfen

Projected Health and Economic Burden of Comorbid Gout and Chronic Kidney Disease in a Virtual US Population: A Microsimulation Study

Rheumatology and therapy., 2024-08, Vol.11 (4), p.913-926

2024

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Two Corticosteroid Pre-Infusion Regimens for Pegloticase in the United States: A Retrospective Analysis in Community Rheumatology Practices

Drugs -- real world outcomes, 2019-12, Vol.6 (4), p.165-171

2019

Link zum Volltext

Verfügbarkeit prüfen

Social Listening in Gout: Impact of Proactive vs. Reactive Management on Self-Reported Emotional States

Rheumatology and therapy., 2024-04, Vol.11 (2), p.301-311

2024

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings

ACR open rheumatology, 2023-08, Vol.5 (8), p.407-418

2023

Link zum Volltext

Verfügbarkeit prüfen

Economic and Health Care Resource Use Burden of Systemic Sclerosis

ACR open rheumatology, 2023-12, Vol.5 (12), p.677-684

2023

Link zum Volltext

Verfügbarkeit prüfen

Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist

Seminars in arthritis and rheumatism, 2016-02, Vol.45 (4), p.e10-e12

2016

Link zum Volltext

Verfügbarkeit prüfen

Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase

Rheumatology and therapy., 2019-06, Vol.6 (2), p.299-304

2019

Link zum Volltext

Verfügbarkeit prüfen

A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis

Pediatric rheumatology online journal, 2018-06, Vol.16 (1), p.41-41, Article 41

2018

Link zum Volltext

Verfügbarkeit prüfen

New-Onset Gout as an Independent Risk Factor for Returning to Dialysis After Kidney Transplantation

Transplantation direct, 2020-12, Vol.6 (12), p.e634-e634

2020

Link zum Volltext

Verfügbarkeit prüfen

Enhancing the Response Rate to Recombinant Uricases in Patients with Gout

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2022-03, Vol.36 (2), p.95-103

2022

Link zum Volltext

Verfügbarkeit prüfen

Treatment Response in Patients with Uncontrolled Gout Co-Treated with Pegloticase and Leflunomide: PUB035

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.801-801

2020

Link zum Volltext

Verfügbarkeit prüfen

Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: A retrospective case series

Medicine (Baltimore), 2024-03, Vol.103 (10), p.e37424-e37424

2024

Link zum Volltext

Verfügbarkeit prüfen

eGFR Changes in Uncontrolled Gout Patients Randomized to Receive Methotrexate or Placebo as Co-Therapy to Pegloticase: MIRROR RCT Findings: SA-PO898

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.851-851

2022

Link zum Volltext

Verfügbarkeit prüfen

eGFR Changes in Uncontrolled Gout Patients Undergoing Pegloticase Plus Methotrexate Co-Therapy: SA-PO897

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.851-851

2022

Link zum Volltext

Verfügbarkeit prüfen

Monosodium urate crystal depletion and bone erosion remodeling during pegloticase treatment in patients with uncontrolled gout: Exploratory dual-energy computed tomography findings from MIRROR RCT

Joint, bone, spine : revue du rhumatisme, 2024-07, Vol.91 (4), p.105715, Article 105715

2024

Link zum Volltext

Verfügbarkeit prüfen

Beyond Medical Treatment: Surgical Treatment of Gout

Current rheumatology reports, 2021-01, Vol.23 (1), p.1-1, Article 1

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety of Pegloticase with Immunomodulation Co-Therapy: Literature Review: PUB318

Journal of the American Society of Nephrology, 2021-10, Vol.32 (10S), p.853-853

2021

Link zum Volltext

Verfügbarkeit prüfen

Risk Factors and Outcomes of Gout in Dialysis Patients: A Cohort Study of the United States Renal Data System (USRDS): PO0792

Journal of the American Society of Nephrology, 2021-10, Vol.32 (10S), p.277-277

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(53)

Sprache

Englisch
(53)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk

Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation

Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial

Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study

Systemic Urate Deposition: An Unrecognized Complication of Gout?

A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study

Comparison Between Early-Onset and Common Gout: A Systematic Literature Review

Projected Health and Economic Burden of Comorbid Gout and Chronic Kidney Disease in a Virtual US Population: A Microsimulation Study

Comparison of Two Corticosteroid Pre-Infusion Regimens for Pegloticase in the United States: A Retrospective Analysis in Community Rheumatology Practices

Social Listening in Gout: Impact of Proactive vs. Reactive Management on Self-Reported Emotional States

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings

Economic and Health Care Resource Use Burden of Systemic Sclerosis

Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist

Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase

A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis

New-Onset Gout as an Independent Risk Factor for Returning to Dialysis After Kidney Transplantation

Enhancing the Response Rate to Recombinant Uricases in Patients with Gout

Treatment Response in Patients with Uncontrolled Gout Co-Treated with Pegloticase and Leflunomide: PUB035

Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: A retrospective case series

eGFR Changes in Uncontrolled Gout Patients Randomized to Receive Methotrexate or Placebo as Co-Therapy to Pegloticase: MIRROR RCT Findings: SA-PO898

eGFR Changes in Uncontrolled Gout Patients Undergoing Pegloticase Plus Methotrexate Co-Therapy: SA-PO897

Monosodium urate crystal depletion and bone erosion remodeling during pegloticase treatment in patients with uncontrolled gout: Exploratory dual-energy computed tomography findings from MIRROR RCT

Beyond Medical Treatment: Surgical Treatment of Gout

Safety of Pegloticase with Immunomodulation Co-Therapy: Literature Review: PUB318

Risk Factors and Outcomes of Gout in Dialysis Patients: A Cohort Study of the United States Renal Data System (USRDS): PO0792

Suchergebnisse filtern